He added, "But we didn't know the exact role they play, or how they work to drive lung cancer progression. I think this study ...

Roche Holding said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer ...

“But we didn’t know the exact role they play, or how they work to drive lung cancer progression. I think this study really ...

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved ...

Roche will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 ...

Roche RHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq ...

In 5-year follow-up data from the phase III CROWN trial of ALK -positive advanced non-small cell lung cancer (NSCLC), ...

What is the life expectancy of someone with interstitial lung disease? Answered by Dr. Howard E. Lewine M.D. Chief Medical ...

The progression-free survival or the disease-free survival was significantly improved with the addition of osimertinib. And I ...

Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, ...

Roche is to end a novel lung cancer treatment trial, the Swiss company confirmed on Thursday, following "disappointing" ...